Biotech Values

[DewDiligence]

VBLT -76%/AH on phase-3 failure of ofra-vec in ovarian cancer:

https://www.globenewswire.com/news-release/2022/07/19/2482252/0/en/VBL-Therapeutics-Announces-Top-Line-Data-from-Phase-3-OVAL-Trial-of-Ofra-Vec-in-Patients-with-Platinum-Resistant-Ovarian-Cancer.html

The OVAL trial demonstrated that patients randomized to the combination of ofra-vec and paclitaxel had a median PFS of 5.29 months, versus 5.36 months for the paclitaxel control arm (HR=1.03). The interim overall survival analysis was also not significantly different between the two study arms (median OS 13.37 months in the treatment arm versus 13.14 months in the control arm; HR= 0.97) and did not support study continuation.